What it is
PEG-MGF is a synthetic analogue of Mechano Growth Factor (MGF), the 24-amino-acid C-terminal E-domain peptide (sequence YQPPSTNKNTKSQRRKGSTFEEHK, peptide MW ≈ 2,948 Da) generated by alternative splicing of the IGF-1 gene. MGF corresponds to the IGF-1Ec isoform in humans (IGF-1Eb in rodents), produced via an exon 4 → exon 5 → exon 6 junction that introduces a 49 bp insert, causing a reading-frame shift and a completely different C-terminus compared to the systemic IGF-1Ea isoform. The E-domain peptide — which lacks the mature IGF-1 receptor-binding domain — is the biologically active fragment studied as exogenous MGF. PEGylation covalently attaches polyethylene glycol chains to the peptide, increasing hydrodynamic radius, total molecular weight (typically 4,000–6,000 Da depending on PEG chain length), and in-vivo stability. Unmodified MGF has a circulating half-life of roughly 5–7 minutes in rodent models; PEGylation is claimed to extend this to the 48–72 hour range by reducing glomerular filtration and shielding the peptide from peptidases — a claim grounded in the broader PEGylated-biologic literature rather than in a peer-reviewed PEG-MGF PK study. MGF is not FDA-approved in any form. PEG-MGF is sold as a research chemical.
How it works
- 01
Alternative splicing of IGF-1 produces a mechanosensitive signal
Goldspink (2010, Endocrinology) reviewed the IGF-1 gene architecture showing that mechanical load and tissue damage shift splicing toward the IGF-1Ec (MGF) transcript. Hill & Goldspink (2003, J Physiol) demonstrated in rat muscle that MGF mRNA rises sharply in the first 24–48 hours after mechanical damage and then declines as systemic IGF-1Ea rises over 5–10 days, producing a temporally separated biphasic growth-factor response. This is the endogenous basis for positioning MGF as an early activation signal rather than a durable anabolic driver.
- 02
Satellite cell activation and the myogenic program
Hill, Wernig & Goldspink (2003, J Anat) linked MGF expression to satellite-cell activation during local muscle injury and repair, coincident with upregulation of M-cadherin, Myf5, and MyoD. Dumont (2015, Semin Cell Dev Biol) placed MGF within the broader satellite-cell activation pathway that drives quiescent muscle stem cells into the cell cycle. The mechanistic point is that MGF is proposed to act on early-phase proliferation of satellite cells, whereas mature IGF-1Ea acts later to promote myoblast differentiation.
- 03
Partial IGF-1R interaction and downstream PI3K/Akt–mTOR signaling
Tonkin (2012, Front Endocrinol) critically reviewed the mechanism and concluded that the MGF E-peptide does not engage the mature IGF-1 receptor in the canonical way (the IGF-1R binding domain is absent from the E-peptide). It is proposed to act through a distinct, still poorly defined tissue-local receptor or accessory mechanism that converges on PI3K/Akt and mTOR to drive protein synthesis and cell survival. The specific receptor identity remains unresolved in 2026 — this is the central unanswered mechanistic question.
- 04
Neurogenesis in the aging brain
Kandalla (2017, Mol Brain) showed that intracerebroventricular delivery of MGF in aged mice increased the number of proliferating neural progenitor cells in the dentate gyrus, rescued age-related decline in adult hippocampal neurogenesis, and improved performance on hippocampus-dependent learning tasks. This is single-lab rodent evidence; no analogous human study exists.
- 05
Cardiac protection after infarction
In a sheep model of myocardial infarction, intracoronary MGF-24aa-E peptide delivery improved post-MI hemodynamic recovery versus mature IGF-1, consistent with PI3K/Akt-mediated cardiomyocyte survival. This is the only published large-animal cardiac data and has not been independently replicated; there is no human cardiac MGF trial.
- 06
The PEGylation half-life claim
The 48–72 hour half-life extension claim is extrapolated from the general PEGylation platform literature (Turecek 2016, Expert Opin Emerg Drugs; Huckaby & Lai 2018; Wang 2024, Front Pharmacol) and the >30 FDA-approved PEGylated biologics (pegfilgrastim, pegaspargase, peginterferon, etc.) that show increased molecular size reduces renal clearance and shields peptides from proteolysis. No peer-reviewed PK study of PEG-MGF specifically in humans or in large animals has been published. The PK extension should be read as a platform-level inference, not a measured parameter for this molecule.
- 07
What is NOT known about the mechanism
The specific MGF receptor has not been identified. Whether PEG-MGF reaches skeletal muscle satellite cells after subcutaneous injection at physiologically relevant concentrations has not been demonstrated in humans. Repeated-dose immunogenicity of the PEG-peptide conjugate — a known concern for PEGylated biologics, where anti-PEG antibodies can accelerate clearance — has not been characterized for this molecule. Dose–response in humans is entirely unstudied.